Recent 8-K filings for ADPT

• May 5, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Adaptive Biotechnologies Q1 revenue $70.9M, up 35% YoY; MRD revenue up 53%; raises FY2026 MRD guidance to $260-270M

  Q1 revenue $70.9M (+35% YoY); MRD revenue $67.1M (+53% YoY); clonoSEQ test volume 32,595 (+41%).

• February 5, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Adaptive Biotechnologies Q4 rev $71.7M (+51% YoY); MRD profitable; FY2026 MRD rev guide $255-265M

  Q4 revenue $71.7M (+51% YoY); FY revenue $277.0M (+55% YoY); net loss narrowed to $13.6M and $59.5M.

• January 12, 2026, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Adaptive Biotechnologies reports preliminary Q4/FY2025 revenue growth of 51%/55% YoY

  Total revenue FY2025 ~$277M (+55% YoY); Q4 ~$72M (+51% YoY).

• November 5, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Adaptive Biotechnologies Q3 revenue $94M (+102% YoY); MRD profitable, guidance raised

  Revenue $94.0M (up 102% YoY) includes $33.7M from full amortization of Genentech payment.

• August 18, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.02

  Adaptive and Genentech terminate cell therapy collaboration; $33.7M non-cash revenue in H2 2025

  Strategic Collaboration and License Agreement with Genentech terminated Aug 13, 2025; effective Feb 9, 2026.

• August 5, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Adaptive Q2 MRD revenue up 42%, achieves MRD profitability; raises FY guidance

  Total revenue $58.9M (+36% YoY); MRD revenue $49.9M (+42% YoY); MRD Adjusted EBITDA positive $1.9M.

• May 1, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Adaptive Biotechnologies Q1 revenue up 25% to $52.4M; raises MRD guidance

  Q1 revenue $52.4M (+25% YoY); MRD revenue $43.7M (+34%); clonoSEQ volume up 36% to 23,117 tests.

• February 11, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Adaptive Biotech Q4 revenue $47.5M; MRD revenue up 31% YoY; FY2025 MRD guidance $175-185M

  Q4 total revenue $47.5M (+4% YoY); full year $179.0M (+5%). MRD revenue $40.1M (+31% Q4, +42% FY).

• November 7, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Adaptive Biotechnologies Q3 revenue $46.4M (+22%); MRD revenue up 52%; net loss narrows to $32.1M

  Revenue $46.4M (+22% YoY); MRD revenue $37.5M (+52%); Immune Medicine $9.0M (-32%).

• August 1, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Adaptive Biotechnologies Q2 MRD revenue up 36% YoY; updates FY guidance

  Total Q2 revenue $43.2M (-12% YoY); MRD revenue $35.3M (+36%), Immune Medicine $7.9M (-66%).

• May 7, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Adaptive Biotechnologies Q1 2024: MRD revenue up 52% to $32.6M; net loss narrows to $47.5M

  Total revenue $41.9M (+11% YoY); MRD $32.6M (+52%), Immune Medicine $9.2M (-43%).

• April 9, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02item 9.01 ◈ executive_change

  Adaptive Biotechnologies appoints Kyle Piskel as CFO effective April 8, 2024

  Kyle Piskel promoted from Principal Accounting Officer to CFO; reports to CEO Chad Robins.

• April 5, 2024, 7:59 PM ET other material materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Adaptive Biotech Q1 prelim rev ~$41-43M (+12% YoY); CFO Peterson departs, Piskel named

  Preliminary total Q1 2024 revenue of ~$41-43M, up ~12% vs Q1 2023.

• February 14, 2024, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01 ◈ Earnings Releases ×3

  Adaptive Biotech Q4 revenue down 17% to $45.8M; net loss widens to $69.5M

  Full year 2023 revenue $170.3M (-8% YoY); MRD revenue $102.7M (+18%) offset by IM decline.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.70 · Most common event earnings

8 positive 1 negative 9 neutral

source · ADPT on sec.gov